Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Safest Option in Trades! (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
The Safest Option in Trades! (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Safest Option in Trades! (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
The Safest Option in Trades! (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Safest Option in Trades! (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
The Safest Option in Trades! (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Safest Option in Trades! (Ad)pixel
China virus protests hit Hong Kong after mainland rallies
Need To Cut Costs? Start With These 10 Money Saving Ideas
The Safest Option in Trades! (Ad)pixel
Is Snowflake Poised for A Rebound After Its Recent Tumble?
China’s Zero-COVID Restrictions Can’t Stop JD.com
The Safest Option in Trades! (Ad)pixel
Check Into The Hotel Rebound With These Welcoming Stocks
Impeachment talk at Trump Org. trial: Did witness misspeak?
NASDAQ:GBT

Global Blood Therapeutics - GBT Stock Forecast, Price & News

$68.49
0.00 (0.00%)
(As of 11/2/2022)
Add
Compare
Today's Range
$68.49
$68.49
50-Day Range
$67.69
$68.49
52-Week Range
$21.65
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.42

Global Blood Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.21 Rating Score
Upside/​Downside
4.5% Downside
$65.42 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.29mentions of Global Blood Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.71) to ($3.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.15 out of 5 stars

Medical Sector

1023rd out of 1,040 stocks

Pharmaceutical Preparations Industry

501st out of 509 stocks

GBT stock logo

About Global Blood Therapeutics (NASDAQ:GBT) Stock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

Global Blood Therapeutics, Inc. (GBT)
GBT Global Blood Therapeutics, Inc.
Where Global Blood Therapeutics Stands With Analysts
8 Analysts Have This to Say About Global Blood Therapeutics
See More Headlines
Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Company Calendar

Last Earnings
11/04/2021
Today
11/28/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GBT
Fax
N/A
Employees
457
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.42
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
-4.5%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

Net Income
$-303,090,000.00
Net Margins
-137.30%
Pretax Margin
-137.01%

Debt

Sales & Book Value

Annual Sales
$194.75 million
Book Value
$3.05 per share

Miscellaneous

Free Float
64,170,000
Market Cap
$4.62 billion
Optionable
Optionable
Beta
0.45

Key Executives

  • Dr. Ted W. Love M.D. (Age 63)
    Pres, CEO & Director
    Comp: $1.06M
  • Mr. Jeffrey S. Farrow (Age 60)
    CFO & Principal Accounting Officer
    Comp: $672.67k
  • Ms. Jung E. Choi (Age 52)
    Chief Bus. & Strategy Officer
    Comp: $645k
  • Mr. David L. Johnson (Age 53)
    Chief Commercial Officer
    Comp: $661.5k
  • Dr. Kim Smith-Whitley M.D. (Age 61)
    Exec. VP and Head of R&D
    Comp: $654k
  • Dr. David R. Phillips
    Founder & Advisor
  • Dr. Matthew P. Jacobson Ph.D.
    Founder & Advisor
  • Dr. Andrej Sali Ph.D.
    Founder & Advisor
  • Ms. Nazila Habibizad (Age 59)
    Exec. VP of Operations
  • Stephanie Yao
    Sr. Director of Corp. Communications & Investor Relations













GBT Stock - Frequently Asked Questions

Should I buy or sell Global Blood Therapeutics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBT, but not buy additional shares or sell existing shares.
View GBT analyst ratings
or view top-rated stocks.

What is Global Blood Therapeutics' stock price forecast for 2023?

14 Wall Street research analysts have issued 12-month price targets for Global Blood Therapeutics' shares. Their GBT share price forecasts range from $31.00 to $75.00. On average, they expect the company's share price to reach $65.42 in the next twelve months. This suggests that the stock has a possible downside of 4.5%.
View analysts price targets for GBT
or view top-rated stocks among Wall Street analysts.

How have GBT shares performed in 2022?

Global Blood Therapeutics' stock was trading at $29.27 at the beginning of the year. Since then, GBT stock has increased by 134.0% and is now trading at $68.49.
View the best growth stocks for 2022 here
.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to the consensus estimate of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. The business's revenue was up 41.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.97) EPS.

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.31%), BlackRock Inc. (7.04%), Pentwater Capital Management LP (4.74%), State Street Corp (3.53%), Perceptive Advisors LLC (3.44%) and UBS Oconnor LLC (3.32%). Insiders that own company stock include Dawn Svoronos, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Nazila Habibizad, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends
.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $68.49.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.62 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

The company employs 457 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.

This page (NASDAQ:GBT) was last updated on 11/29/2022 by MarketBeat.com Staff